Gerd Mander - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Gerd Mander

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Clinical Neuropharmacology|August 1, 2009

Experimental conditions substantially influence botulinum toxin potency testingGerd Mander, Klaus Fink, Martin Vey

Journal of Neural Transmission (Vienna, Austria : 1996)|October 6, 2011

Measuring the potency labelling of onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin (®)) in an LD50 assayDirk Dressler, Gerd Mander, Klaus Fink

Acta Crystallographica. Section D, Biological Crystallography|March 25, 2004

Determination of a novel structure by a combination of long-wavelength sulfur phasing and radiation-damage-induced phasingManfred S Weiss, Gerd Mander, Reiner Hedderich, et al.

Pageof 1

Search research articles

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Clinical Neuropharmacology|August 1, 2009

Experimental conditions substantially influence botulinum toxin potency testingGerd Mander, Klaus Fink, Martin Vey

Journal of Neural Transmission (Vienna, Austria : 1996)|October 6, 2011

Measuring the potency labelling of onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin (®)) in an LD50 assayDirk Dressler, Gerd Mander, Klaus Fink

Acta Crystallographica. Section D, Biological Crystallography|March 25, 2004

Determination of a novel structure by a combination of long-wavelength sulfur phasing and radiation-damage-induced phasingManfred S Weiss, Gerd Mander, Reiner Hedderich, et al.

Pageof 1